CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CareDx Inc.

BMO Capital analyst Etienne Ricard maintained a Hold rating on Canadian Tire today and set a price target of C$180.00. Ricard covers the Financial ...

BMO Capital Remains a Hold on Canadian Tire (CDNAF)

In a report released yesterday, Tamy Chen from BMO Capital maintained a Hold rating on Canadian Tire, with a price target of C$180.00. The company’...

Canadian Tire (CDNTF) Receives a Hold from BMO Capital

CareDx ( ($CDNA) ) has shared an announcement. On November 4, 2025, CareDx announced its third-quarter financial results, highlighting a 21% year-o...

CareDx Reports Strong Q3 Financial Results

The latest announcement is out from CareDx ( ($CDNA) ). On October 22, 2025, CareDx, Inc. appointed Suresh Gunasekaran as a Class II director. Mr. ...

Market Cap	$883.65M	P/E Ratio	N/A
52W High	$26.37	52W Low	$10.96
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	54.6%	52W Position	40.4%
Overall Score	69	Value Score	80
Quality Score	--	Technical Score	58

EPS Current Est	$-0.51	EPS Next Est	$-0.21
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CDNA	$17.18	+9.01%	797.32K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CDNA	$17.18	+9.0%	797.32K
3
4
5
6

CDNA

CDNA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get CareDx Inc. Data in Excel

Get CareDx Inc. Data in Excel